ApoB is a particularly sensitive indicator of changes in glycemic control, so it is possible that tight glycemic control (reduction of insulin resistance in our study) may have ‘antiatherogenic’ effects by lowering ApoB levels (which were also lowered in our study). This evidence concerns the gene APOB and Insulin resistance.